Oral Antifungal Drugs: 8 Key Treatments And Uses
Comprehensive guide to oral antifungals for treating systemic and superficial fungal infections effectively.
Oral antifungal drugs are essential for managing superficial and systemic mycoses, particularly when topical therapies fail or for widespread infections. These agents target fungal cell membranes, walls, or synthesis pathways, with azoles, allylamines, and polyenes being primary classes used orally.
Indications for Oral Antifungal Therapy
Oral antifungals are indicated for extensive dermatophytoses (tinea infections beyond 10-20% body surface), onychomycosis, chronic mucocutaneous candidiasis, pityriasis versicolor unresponsive to topicals, and severe scalp infections like tinea capitis in adults. Systemic indications include invasive candidiasis, aspergillosis, and prophylaxis in immunocompromised patients.
- Dermatophyte infections: Tinea corporis, cruris, pedis, barbae, capitis, manuum, and onychomycosis.
- Candidiasis: Oropharyngeal, esophageal, chronic mucocutaneous, and systemic forms.
- Malassezia infections: Extensive pityriasis versicolor.
- Deep mycoses: Histoplasmosis, coccidioidomycosis, blastomycosis (off-label in some regions).
Selection depends on fungal species, site, patient factors like age, liver function, and drug interactions.
Classes of Oral Antifungals
Oral antifungals are classified by mechanism: ergosterol synthesis inhibitors (azoles, allylamines), polyenes, and others like griseofulvin.
Azole Antifungals
Azoles inhibit lanosterol 14α-demethylase, disrupting ergosterol synthesis and fungal membrane integrity. Imidazoles (ketoconazole, miconazole) have broader but more toxic profiles; triazoles (fluconazole, itraconazole, voriconazole, posaconazole) offer better safety and spectrum.
| Drug | Spectrum | Formulations |
|---|---|---|
| Fluconazole | Candida spp., C. neoformans, dermatophytes (variable) | Capsules, suspension, IV |
| Itraconazole | Dermatophytes, Candida, dimorphic fungi, Aspergillus (fair) | Capsules, solution, tablets |
| Voriconazole | Candida, Aspergillus, molds | Tablets, suspension |
| Posaconazole | Broad: Candida, molds, zygomycetes | Tablets, suspension |
Allylamines and Others
Terbinafine inhibits squalene epoxidase, causing fungal cell death; highly effective against dermatophytes. Griseofulvin binds microtubules, impairing mitosis; used for tinea capitis.
Terbinafine
Mechanism: Inhibits ergosterol synthesis at squalene epoxidase step, fungicidal for dermatophytes.
Indications: Onychomycosis (toenails 12 weeks, fingernails 6 weeks), tinea pedis (2-4 weeks), capitis (4 weeks), corporis/cruris (2-4 weeks). Off-label for Majocchi granuloma.
Dose: Adults: 250 mg daily. Children (>40 kg): 250 mg; 20-40 kg: 125 mg; <20 kg: 62.5 mg. Take with food if GI upset.
Side effects: Rare hepatotoxicity (0.2-0.7%), taste disturbance (1-3%), GI upset. Monitor LFTs at baseline and if symptoms arise.
Interactions: Minimal CYP450 induction; caution with warfarin, caffeine.
Griseofulvin
Mechanism: Binds keratin, deposited in skin/nails; fungistatic via microtubule inhibition.
Indications: Tinea capitis (8 weeks), onychomycosis (6-12 months).
Dose: Ultramicrosize: 10-15 mg/kg/day (max 1 g); take with high-fat meal for absorption.
Side effects: Headache, nausea, photosensitivity, rare leukopenia. Teratogenic; avoid in pregnancy.
Fluconazole
Mechanism: Inhibits CYP51 (lanosterol demethylase); fungistatic.
Indications: Dermatophyte infections (tinea corporis 150-300 mg/week 2-6 weeks), pityriasis versicolor (300 mg/week 2 weeks), candidiasis.
Dose: Adults: Varies by indication; e.g., onychomycosis 150-450 mg/week. Renal adjustment needed.
Side effects: Nausea (4%), rash (2%), rare QT prolongation, hepatotoxicity. Safe in pregnancy for vulvovaginal candidiasis.
Itraconazole
Mechanism: Broad-spectrum triazole; variable bioavailability.
Indications: Onychomycosis (pulse: 200 mg BID 1 week/month x3), tinea capitis, systemic mycoses.
Dose: Capsules with food; solution empty stomach. Pulse therapy preferred for nails.
Side effects: Hepatotoxicity (1/10,000), hypokalemia, edema, negative inotropy. Monitor LFTs, ECG.
Ketoconazole
Restricted due to hepatotoxicity; rarely used orally for systemic infections refractory to others.
Polyenes: Nystatin
Mechanism: Binds ergosterol, forms pores; poorly absorbed orally.
Indications: Oral candidiasis (thrush); swish-and-swallow suspension.
Dose: 100,000 units 4x daily; safe for infants.
Voriconazole and Posaconazole
Reserved for invasive infections: voriconazole for aspergillosis/candidemia; posaconazole for refractory oropharyngeal candidiasis and prophylaxis.
Dose: Voriconazole: 200-400 mg BID (weight-adjusted); posaconazole: 300 mg/day tablets.
Side effects: Visual changes (voriconazole 30%), QT prolongation, photosensitivity.
Drug Interactions
Azoles inhibit CYP3A4 (itraconazole, ketoconazole strongest; fluconazole weakest), increasing levels of statins, warfarin, oral contraceptives, antiretrovirals. Proton pump inhibitors reduce azole absorption. Terbinafine induces CYP2D6 minimally.
| Drug | Major Interactions |
|---|---|
| Itraconazole | Statins (rhabdomyolysis), digoxin, cyclosporine |
| Fluconazole | Warfarin, phenytoin, rifampin (inducer) |
| Voriconazole | Sirolimus, tacrolimus, methadone |
Monitoring and Safety
Baseline LFTs for all systemic antifungals; repeat if symptoms or prolonged therapy (>1 month). ECG for QT risk (azoles). Pregnancy: Avoid teratogens (griseofulvin, systemic azoles except fluconazole low-dose).
- Hepatotoxicity: Terbinafine, azoles; incidence 1:10,000-1:100,000.
- Resistance: Emerging in Candida glabrata/krusei to fluconazole.
- Pediatrics: Weight-based dosing; fluconazole, terbinafine preferred.
Pulse and Continuous Therapy
Pulse regimens (itraconazole, terbinafine) reduce duration/exposure: e.g., itraconazole 200 mg BID 1 week/month x2-3 for onychomycosis, mycologic cure 63% vs. 36% continuous.
Special Populations
Pregnancy: Topical preferred; fluconazole 150 mg safe for vaginal candidiasis.
HIV/Immunocompromised: Prophylaxis with fluconazole/posaconazole; treat thrush with systemic azoles.
Children: Terbinafine granules for tinea capitis; griseofulvin alternative.
Frequently Asked Questions (FAQs)
Q: Which oral antifungal is first-line for onychomycosis?
A: Terbinafine 250 mg daily for 12 weeks (toenails); highest cure rates ~76% mycologic.
Q: How to manage azole-induced hepatotoxicity?
A: Discontinue if ALT >3x ULN with symptoms; monitor LFTs monthly initially.
Q: Is fluconazole safe in pregnancy?
A: Single 150 mg dose for vaginal candidiasis is category D but low risk; avoid high doses.
Q: What if topical antifungals fail for tinea pedis?
A: Oral terbinafine or itraconazole 2-4 weeks.
Q: Duration for tinea capitis in children?
A: Terbinafine 4 weeks or griseofulvin 8 weeks, plus adjunctive shampoo.
References
- Antifungal Agents – StatPearls — NCBI Bookshelf. 2023-07-17. https://www.ncbi.nlm.nih.gov/books/NBK538168/
- Antifungal Medications – Merck Manuals — Merck & Co. 2024-05-01. https://www.merckmanuals.com/professional/infectious-diseases/fungal-infections/antifungal-medications
- 8 Oral Antifungal Medications and How They Differ — GoodRx Health. 2024-02-15. https://www.goodrx.com/conditions/fungal-infection/oral-antifungal-medication
Similar Articles
Read full bio of Sneha Tete
